UBS Group’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $70.7K | Buy |
52,788
+14,448
| +38% | +$23.8K | ﹤0.01% | 7185 |
|
|
2025
Q4 | $61.3K | Sell |
38,340
-5,202
| -12% | -$10.7K | ﹤0.01% | 7124 |
|
|
2025
Q3 | $111K | Buy |
43,542
+3,660
| +9% | +$11.5K | ﹤0.01% | 7043 |
|
|
2025
Q2 | $72.2K | Sell |
39,882
-61,896
| -61% | -$102K | ﹤0.01% | 7490 |
|
|
2025
Q1 | $207K | Buy |
101,778
+21,972
| +28% | +$82K | ﹤0.01% | 6540 |
|
|
2024
Q4 | $478K | Buy |
79,806
+78,979
| +9,550% | +$660K | ﹤0.01% | 5881 |
|
|
2024
Q3 | $8.07K | Sell |
827
-2,453
| -75% | -$33K | ﹤0.01% | 7854 |
|
|
2024
Q2 | $67.2K | Sell |
3,280
-5,917
| -64% | -$198K | ﹤0.01% | 6455 |
|
|
2024
Q1 | $415K | Buy |
9,197
+6,177
| +205% | +$295K | ﹤0.01% | 5345 |
|
|
2023
Q4 | $143K | Sell |
3,020
-1,893
| -39% | -$105K | ﹤0.01% | 5980 |
|
|
2023
Q3 | $199K | Sell |
4,913
-2,021
| -29% | -$204K | ﹤0.01% | 5386 |
|
|
2023
Q2 | $739K | Sell |
6,934
-3,084
| -31% | -$1.03M | ﹤0.01% | 4505 |
|
|
2023
Q1 | $2.99M | Buy |
10,018
+1,317
| +15% | +$562K | ﹤0.01% | 3008 |
|
|
2022
Q4 | $2.99M | Sell |
8,701
-261
| -3% | -$63.1K | ﹤0.01% | 2979 |
|
|
2022
Q3 | $1.7M | Buy |
8,962
+1,648
| +23% | +$383K | ﹤0.01% | 3299 |
|
|
2022
Q2 | $1.54M | Sell |
7,314
-3,971
| -35% | -$835K | ﹤0.01% | 3357 |
|
|
2022
Q1 | $3.78M | Sell |
11,285
-1,211
| -10% | -$351K | ﹤0.01% | 2815 |
|
|
2021
Q4 | $4.06M | Sell |
12,496
-987
| -7% | -$424K | ﹤0.01% | 3051 |
|
|
2021
Q3 | $6.55M | Buy |
13,483
+3,445
| +34% | +$1.51M | ﹤0.01% | 2400 |
|
|
2021
Q2 | $4.67M | Sell |
10,038
-2,298
| -19% | -$1.25M | ﹤0.01% | 2751 |
|
|
2021
Q1 | $8.52M | Buy |
12,336
+6,589
| +115% | +$5.3M | ﹤0.01% | 2100 |
|
|
2020
Q4 | $4.25M | Buy |
5,747
+253
| +5% | +$197K | ﹤0.01% | 2621 |
|
|
2020
Q3 | $3.81M | Buy |
5,494
+439
| +9% | +$330K | ﹤0.01% | 2449 |
|
|
2020
Q2 | $4.29M | Sell |
5,055
-353
| -7% | -$230K | ﹤0.01% | 2161 |
|
|
2020
Q1 | $1.93M | Sell |
5,408
-410
| -7% | -$147K | ﹤0.01% | 2795 |
|
|
2019
Q4 | $1.36M | Buy |
5,818
+824
| +16% | +$82.8K | ﹤0.01% | 3925 |
|
|
2019
Q3 | $563K | Buy |
4,994
+271
| +6% | +$42.7K | ﹤0.01% | 4465 |
|
|
2019
Q2 | $828K | Buy |
4,723
+30
| +0.6% | +$5.08K | ﹤0.01% | 3899 |
|
|
2019
Q1 | $743K | Buy |
4,693
+3,898
| +490% | +$481K | ﹤0.01% | 3785 |
|
|
2018
Q4 | $49K | Buy |
795
+551
| +226% | +$46.5K | ﹤0.01% | 6102 |
|
|
2018
Q3 | $30K | Buy |
244
+44
| +22% | +$6.53K | ﹤0.01% | 6537 |
|
|
2018
Q2 | $29K | Buy |
200
+34
| +20% | +$5.19K | ﹤0.01% | 6406 |
|
|
2018
Q1 | $27K | Buy |
+166
| New | +$27.7K | ﹤0.01% | 6175 |
|
Other funds holding BTAI
AC
OCM
VCM
VFT
UBS Group's BTAI Position: Q1 2026 in Review
UBS Group increased its BioXcel Therapeutics (BTAI) stake by 38% in Q1 2026, buying an estimated $23.8K and bringing the position to 52,788 shares worth $70.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7185.
UBS Group first reported a position in BTAI in Q1 2018 and has held it in 33 quarters since. The position peaked at $8.52M in Q1 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.
- UBS Group held 52,788 shares of BioXcel Therapeutics worth $70.7K as of Q1 2026.
- UBS Group bought 14,448 BioXcel Therapeutics shares in Q1 2026, an estimated $23.8K.
- BioXcel Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7185 holding.
- UBS Group first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 33 quarters since.
- UBS Group's BioXcel Therapeutics position peaked at $8.52M in Q1 2021.
- 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.